EGPA disease burden in Europe and US: evidence from real-world clinical practice

Résumé fourni par la source

Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis affecting small-to-medium blood vessels with multisystem organ involvement. This retrospective, observational, real-world study characterised the EGPA disease burden. Methods: Data drawn from the Adelphi Real World EGPA Disease Specific ProgrammeTM, a cross-sectional survey of physicians and patients (pts) in Europe and US conducted between July–December 2023 were analysed descriptively. Physicians who managed ≥2 pts with EGPA reported demographics, symptoms, organ damage, asthma exacerbations and hospitalisations for their next 4–5 consecutively consulting pts (≥10 years old, with a physician-confirmed EGPA diagnosis). Results: Overall, 121 physicians provided data on 503 pts. Mean (SD) pt age was 50 (15) years, 50% were male, 89% were White and 22% required caregiver support. Pts had a mean (SD) of 3 (3) symptoms at data capture, the most common shown in the Figure. 72% of pts had physician-determined EGPA-induced organ damage, commonly affecting the pulmonary system (Figure). In the past year, 72/406 (18%) pts had been hospitalised, 51/72 (71%) due to EGPA complications. Of 277 pts (55%) with concomitant asthma, 83 (30%) had an asthma exacerbation in the past year; of those, 20 (24%) were hospitalised. Conclusion: Pts with EGPA have substantial disease burden, impacting multiple organs, with high rates of asthma exacerbations and hospitalisations. erj;66/suppl_69/PA3667/F1 F1 F1

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.